A newly characterized metabolite in urine could one day help predict whether tuberculosis treatment is working or not. Concentration of the glycopeptide, which researchers believe is a metabolite of a protein called plasma protease C1 inhibitor — increase significantly in the urine of people with active pulmonary tuberculosis. In people who respond to treatment, metabolite levels dip back toward normal within a week (ACS Infect. Dis. 2018, DOI: 10.1021/acsinfecdis.8b00241). Though this initial study is small, such a test could help identify whether a candidate TB drug is likely to succeed or fail.
Items tagged with Diagnostics
Urine testing of people with HIV for TB can save lives and be cost-effective (post)
Screening all hospitalized patients with HIV for tuberculosis (TB) using urine tests would improve life expectancy and be cost-effective in Malawi and South Africa. These findings from an international team of investigators have been published in The Lancet Global Health and could influence international guidelines on TB testing.
Webinar series 2019: Next-generation sequencing for DR-TB (post)
FIND, the World Health Organization, the Stop TB Partnership's New Diagnostics Working Group and Médecins Sans Frontières Access Campaign are co-organizing a four-part webinar series on the use and implementation of next-generation sequencing for drug-resistant TB (DR-TB) in February 2019.
Urine metabolite could signal tuberculosis treatment success (post)
Drug-resistant TB: high mortality rate due to inaccurate tests (post)
Inaccurate tests carried out on tuberculosis patients in developing countries often fail to reliably detect resistance to drugs, leading to incorrect treatment and a higher mortality rate. These are the results of study by an international group of researchers led by a team at the University of Bern published today (January 8).
Akonni Biosystems awarded Phase II NIH contract to advance its device to purify DNA from sputum for TB testing (post)
Frederick, MD — February 5, 2019 — Akonni Biosystems, a molecular diagnostics (MDx) company that develops, manufactures, and intends to market advanced MDx systems, today announced receipt of a $3 million, three-year Phase II Small Business Innovation Research (SBIR) contract from the National Institute of Allergy and Infetious Diseases (NIAID) at the National Institutes of Health (NIH). Akonni received the Phase I contract in August 2016. During phase I, Akonni successfully completed each milestone set forth by the NIH, resulting in a simple device that can process high-volume sputum samples for sensitive Mycobacterium tuberculosis detection at smear-negative, culture-positive levels. Akonni is collaborating with Dr. Nicole Parrish, an Associate Professor of Pathology/Director of Mycobacteriology at the Johns Hopkins University School of Medicine with over 25 years of experience in Tuberculosis (TB) diagnostics, and MRIGlobal, who will be testing the systems.
Precision immunoprofiling could help reduce latent tuberculosis infection (post)
ANN ARBOR—New diagnostic tools such as machine learning and precision medicine could help identify tuberculosis patients with the highest risk of reactivation of the disease, according to a new University of Michigan study.
ImmunoPrecise Antibodies collaborates with FIND to help advance new TB diagnostic test (post)
VICTORIA, February 19, 2019 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the publication of the results of a research collaboration project with the Foundation for Innovative New Diagnostics (FIND) where IPA developed rabbit monoclonal antibodies (mAbs) for assessment in FIND’s sensitive new immunoassay diagnostic test for tuberculosis (TB). IPA developed rabbit monoclonal antibodies, using its B cell Select platform, that recognize lipoarabinomannan (LAM), a lipopolysaccharide target and biomarker for TB that can be excreted in the urine of individuals with the disease. Two of these antibodies, when combined with others to form capture-detection pairs and a sensitive chemical detection reagent, were highly specific for LAM and sensitive enough to detect LAM in urine samples.
TGen and ABL pursue global rollout of advanced TB test (post)
FLAGSTAFF, Ariz., and LUXEMBOURG CITY, Luxembourg — March 18, 2019 — In an important step toward eradicating tuberculosis (TB), the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has signed a licensing agreement with an international biomedical firm, Advanced Biological Laboratories (ABL), to market and distribute TGen’s patented Next Generation Sequencing based TB test technology.
Promising diagnostics for detecting latent TB revealed (post)
A collaboration between the National Center for Supercomputing Applications (NCSA) at the University of Illinois, Mayo Clinic, and the University of Michigan are introducing a new machine-learning-driven approach to latent tuberculosis infections (LTBI) diagnostics. While leveraging a high throughput detection technology and powerful bioinformatics, this approach aims to reveal multi-marker signatures for LTBI diagnosis and risk stratification.
Page 32 of 70 · Total posts: 0
←First 31 32 33 Last→